BIO Financial Facts
Cost of goods sold: 236.55MNet income attributable to Bio-Rad: 18.01M
See Full Income Statement
Additional paid-in capital: 316.75M
Total liabilities and stockholders' equity: 3.87B
See Full Balance Sheet
Bio-Rad Laboratories, Inc. (BIO) Earnings
|
Expand Research on BIO
| Next EPS Date | 5/7/24 | EPS Growth Rate | -30.8% |
|---|---|---|---|
| Average EPS % Beat Rate | -1.6% | Revenue Growth Rate | -7.0% |
| Average % Move 1-Wk after EPS | -5.7% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/2/17 |  |
Q317 | $0.91 | $0.38 | +$0.53 | $535M | $508M | = |  | | Details |
| 2/28/19 | |
Q418 | $2.13 | $1.70 | +$0.43 | $617.5M | $609.02M | N/A | | | Details |
| 5/8/18 | |
Q118 | $1.17 | $1.07 | +$0.10 | $551.5M | $527.2M | = | | | Details |
| 8/1/19 | |
Q219 | $1.57 | $1.33 | +$0.24 | $572.6M | $566.19M | N/A | | | Details |
2/26/15  |
|
Q414 | $1.34 | $1.18 | +$0.16 | $598.2M | $593.41M | N/A | | | Details |
| 11/1/16 |
|
Q316 | $0.62 | $0.51 | +$0.11 | $508.7M | $480.6M | N/A | | | Details |
| 2/13/20 | |
Q419 | $2.32 | $2.44 | -$0.12 | $624.4M | $641.95M | N/A | | | Details |
| 2/16/23 | Q422 | $3.31 | $3.47 | -$0.16 | $730.3M | $747.26M | N/A | | | Details |
